PWAM
RXRX icon

Private Wealth Asset Management’s Recursion Pharmaceuticals RXRX Stock Holding History

Private Wealth Asset Management’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-154
Closed -$473 – 958
2026
Q1 		$473 Buy
+154
New +$595 ﹤0.01% 900

Other funds holding RXRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Private Wealth Asset Management's RXRX Position: Q2 2026 in Review

Private Wealth Asset Management sold out of Recursion Pharmaceuticals (RXRX) in Q2 2026, closing a stake of 154 shares — an estimated $473 sold.

Private Wealth Asset Management first reported a position in RXRX in Q1 2026 and held it in 1 quarter. The position peaked at $473 in Q1 2026. 342 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

  • Private Wealth Asset Management reported no remaining Recursion Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Private Wealth Asset Management sold 154 Recursion Pharmaceuticals shares in Q2 2026, an estimated $473.
  • Private Wealth Asset Management first reported a position in Recursion Pharmaceuticals in Q1 2026 and held it in 1 quarter.
  • Private Wealth Asset Management's Recursion Pharmaceuticals position peaked at $473 in Q1 2026.
  • 342 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Private Wealth Asset Management's 13F filing for Q2 2026, filed 11 Aug 2026.